CNBC Markets Now: July 1, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
31 minutes ago
- CNBC
A bare-bones deal is Europe's best hope in trade talks with the U.S., sources say
The clock is ticking in trade talks between Washington and the European Union, with European officials now saying their best hope is striking a "political" deal before a key July 9 deadline, three sources told CNBC. Concrete details of such a trade arrangement would have to be worked out at a later time. "The U.S. proposal from last week is aimed at an agreement in principle," one EU official, who did not want to be named due to the sensitivity of the talks, told CNBC, adding that this agreement in principle would then "be negotiated out into a proper trade agreement at a later stage." Previously close allies, the U.S. and EU have had a fractious relationship amid disagreements over trade and support for embattled Ukraine in the months since the start of U.S. President Donald Trump's second term. Tensions escalated in early April, when White House announced a spate of reciprocal tariffs against most global trade partners, including a 20% levy on the EU. All such duties have been temporarily reduced until July 9 to facilitate talks. The U.S. sent a new proposal to the EU's negotiating team last week. European negotiators are having face-to-face talks with their American counterparts later this week with the view to get a deal done in the coming days. Total bilateral trade in goods between the EU and the U.S. accounted for 851 billion euros ($1 trillion) in 2023, according to figures from the European Commission. European officials expect a new update on the negotiations Friday, but the situation is fluid. On Monday, European ambassadors had conversations about the state of play in the trade negotiations. Lithuania's Minister of Finance Rimantas Šadžius told CNBC on Wednesday that he is "slightly optimistic" there will be a trade compromise between both sided of the Atlantic. Despite this, sources told CNBC that, despite efforts to reach a trade compromise, the EU is preparing for any possible outcomes, including the return of reciprocal tariffs. "The general sense is that in the coming days and weeks, all outcomes, ranging from a successful deal on a framework agreement all the way to higher US tariffs with additional sectors, are still possible," the same EU official told CNBC. This sentiment was also shared by European Commission President Ursula von der Leyen last Friday. "We are ready for a deal. At the same time, we are preparing for the possibility that no satisfactory agreement is reached," she said at a press conference. The European Commission was not immediately available for comment when contacted by CNBC Wednesday about an update to the talks. Another EU official, also speaking to CNBC on the condition of anonymity, said there is an awareness in Brussels that it is almost impossible to return to the trade relationship that the EU and U.S. enjoyed before the April 2 announcement of reciprocal tariffs. A third EU official, who also chose to speak anonymously, told CNBC that there is a risk that the outcome of the talks will be an "asymmetrical" deal, under which the EU will not escape some additional U.S. levies. Nonetheless, the bloc is looking to get concessions in critical areas for its economy, including automotive, semiconductors and pharmaceuticals, all three sources confirmed. The first EU official added that some member states will only agree to a deal in principle if there is a commitment from the Trump administration to "upfront tariff relief." The European Commission, the executive arm of the EU, negotiates trade with other parts of the world, but its proposals and position reflects the thinking of the 27 capitals.
CNBC
an hour ago
- CNBC
Tax changes for high earners: Here's what to know
CNBC's Robert Frank joins 'Squawk Box' with a look at the impact of President Trump's tax and spending bill on high earners and investors.
CNBC
an hour ago
- CNBC
London stock market could weather its biggest blow yet if AstraZeneca exits
Pressure is piling on London's stock exchange, with reports that British pharma giant AstraZeneca may move its listing to the U.S. delivering yet another blow this week. CEO Pascal Soriot is considering moving the company's stock listing from London to the U.S., British newspaper The Times reported on Tuesday afternoon, citing anonymous sources. Soriot's frustrations with the U.K.'s regulatory environment — particularly rules around new medicine approvals and drug pricing systems — are said to be driving the move. AstraZeneca declined to comment on the Times report. The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable business listed on London's FTSE 100. AstraZeneca's market cap was £161.2 billion ($221.1 billion) as of Tuesday's closing price, according to LSEG data. AstraZeneca's potential transatlantic move would add to concerns around London's weakening status as a global financial hub. A number of companies have delisted from the London market or reconsidered plans to float shares in the city over the past year. Toni Meadows, head of investment at London's BRI Wealth Management, labeled AstraZeneca's rumored listing considerations as "disappointing" for the U.K. equity market — but he conceded that "it is not surprising" given that it would form the latest development in a wider established trend. Earlier this year, reports emerged that Chinese fast fashion giant Shein was looking to list in Hong Kong instead of London, when it goes public. Last week, news agency Reuters reported that the company was planning to file confidentially for a Hong Kong IPO. Metals investor Cobalt Holdings, meanwhile, confirmed to CNBC last month that it had scrapped plans for a London IPO, while British fintech giant Wise announced in June that it was moving its primary listing from London to New York. Kristo Kaarmann, Wise's CEO and co-founder, said in a statement at the time that the move would help raise awareness of the company in the U.S., while giving the firm better access to "the world's deepest and most liquid capital market." Companies listed in London have historically had much lower valuations than their Wall Street counterparts. Research from British investment manager Rathbones last year showed that the forward price-to-earnings ratio for U.K. stocks was 32% lower than those listed in the U.S. on a like-for-like basis. On the flipside, the Financial Times reported last week that Norwegian software giant Visma had chosen London for its upcoming debut on the public market. "Large and important companies like AstraZeneca are seeking a valuation uplift from exposure to a wider investor base and they will get that from moving to a US listing," BRI's Meadows told CNBC via email on Wednesday. "The trend to move listing, or the stream of takeovers for UK listed stocks, highlights value in the UK equity market, but it does nothing to encourage a new supply of companies listing here to support the future standing of the index in a Global context," Meadows added. Claire Trachet, founder of M&A advisory Trachet, said AstraZeneca shifting its listing to New York would represent "a memorable loss" for the London Stock Exchange. "Given the complexity of the company, this isn't simply because of liquidity or valuation advantages often cited by departing firms, rather a trifecta of underperforming capital markets, regulatory constraints, and misaligned incentives that make it harder to scale and reward innovation at home," she told CNBC by email. Trachet added that London-listed companies with a combined value in excess of $100 billion had already made the move to New York in recent years — and AstraZeneca's departure alone would more than double that figure. "The potential move makes it painfully clear to global markets that the UK is losing its edge on the needs of world-class, scale-driven companies," she said. "This isn't an isolated story — and that's the biggest issue. It's part of a broader shift, where founders and boards are increasingly looking to the US for deeper capital, stronger support, and a more ambitious investor base." Tom Bacon, a London-based partner at global law firm BCLP — which has a division dedicated to M&A and corporate finance — labeled reports of AstraZeneca's Soriot's desire to shift away from London "very worrying." "I think this should sound the alarm for the UK government that they need to do more both to support the city and our stock market together with our critical industries like life sciences and pharmaceuticals," he said. Dan Coatsworth, investment analyst at AJ Bell, on Wednesday said that AstraZeneca's reported plans appeared to be driven by business needs rather than chasing a higher valuation — but he added that moving the company's listing across the Atlantic "won't be an easy move to pull off." "Unlike many other UK market 'defectors' with a dominant US shareholder base like CRH and Flutter, AstraZeneca has a more geographically diverse pool of investors," he explained in an email. However, Coatsworth noted that AstraZeneca generates around 42% of its sales from the U.S., and already has plans to increase its operational footprint in the country. Earlier this year, CEO Soriot told CNBC AstraZeneca was "very committed to the United States," where the company has two large research and development centers. AJ Bell's Coatsworth told CNBC that AstraZeneca's CEO could also see a full U.S. stock listing as a "stepping stone to receiving better treatment Stateside." European pharmaceutical companies are facing uncertainty around their future in the American market, where U.S. President Donald Trump has threatened to impose sector-specific tariffs on drug imports. While the industry was exempted from Trump's so-called reciprocal tariffs plans when they were unveiled in April, the White House leader has since placed the sector under investigation by the U.S. Commerce Department, warned tariffs on pharma are "coming soon," and signed an executive order directing medicine manufacturers to lower the price of some drugs in line with costs paid overseas.
